Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
25. April 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Veru Announces Date of 2024 Annual Meeting of Shareholders
01. April 2024 16:05 ET
|
Veru Inc.
--2023 Form 10-K/A and Q1 2024 Form 10-Q filed today-- --2024 Annual Meeting of Shareholders will be June 18, 2024 -- MIAMI, FL, April 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late...
Veru Reschedules Annual Meeting of Shareholders
22. März 2024 16:05 ET
|
Veru Inc.
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings-- MIAMI, FL, March 22,...
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
12. März 2024 08:00 ET
|
Veru Inc.
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality...
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
27. Februar 2024 19:15 ET
|
Veru Inc.
MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher...
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
20. Februar 2024 08:30 ET
|
Veru Inc.
MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality...
Veru Reports Fiscal 2024 First Quarter Financial Highlights
08. Februar 2024 06:30 ET
|
Veru Inc.
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone— —Company to...
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
06. Februar 2024 08:30 ET
|
Veru Inc.
FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone ...
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
31. Januar 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for obesity, oncology, and viral induced...
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
25. Januar 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology,...